AG Mednet, Biovisiq team up to bring clinical trial solutions to Asian market
Executing its mission to bring zero-delay imaging technology to clinical trials around the world, AG Mednet has signed a Master Services Agreement with Biovisiq, a Japanese imaging core laboratory (ICL), with an aim to set the new industry standard for imaging data quality, compliance and efficiency.
According to industry research, more than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks. The AG Mednet Submission Quality and Compliance module immediately detects errors that result in query stoppages and gives ICLs a system to verify information, automatically update support systems including EDC (electronic data capture), and dramatically reduce the amount of queries returned for correction or re-scanning. In clinical trials conducted using AG Mednet technology, sponsors experience a more than 75% query reduction rate, resulting in significant cost savings and faster decision times.
“Biovisiq is dedicated to providing reliable, cost-effective and compliant imaging services to Japan and the growing Asian pharmaceutical market. We are confident that our partnership with AG Mednet will help accomplish this goal,” said Shigeto Ogawa, president and CEO of Biovisiq.
“Asia is the next frontier in clinical trial research as recruitment in the U.S. and Western Europe is getting harder to achieve,” said Abraham Gutman, president and CEO of AG Mednet. “As clinical trials move closer to the patient base across Asia, we look forward to working with the talented team at Biovisiq to make a significant contribution to the Asia and Japan-specific drug discovery and development markets.”